CAPRA-EVO Trial Evaluates Early Evolocumab in Acute Coronary Syndrome Patients
The CAPRA-EVO trial is assessing the efficacy of early evolocumab in reducing coronary plaque progression in ACS patients.
Asset / Drug
Drug and asset intelligence for evolocumab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.